Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DURECT CORPDRRX · Entity 75335 | Director | June 17, 2020 | June 18, 2020 |
| Vistagen Therapeutics, Inc.VTGN · Entity 7955 | Director | September 09, 2025 | September 11, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DURECT CORP
Report date June 17, 2020 · Filed June 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.33 · Expires 2030-06-17 | Direct | 55,000 |
Reported balance
After 2020-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-17 · Grant · Acquired 55,000 · Balance 55,000 F1: 100% of the total shares of this Grant Dated June 17, 2020 shall vest on the day before the first year anniversary of the Grant Date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the total shares of this Grant Dated June 17, 2020 shall vest on the day before the first year anniversary of the Grant Date.
Vistagen Therapeutics, Inc.
Report date September 09, 2025 · Filed September 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.61 · Expires 2035-09-09 | Direct | 17,600 |
Reported balance
After 2025-09-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-09-09 · Grant · Acquired 17,600 · Balance 17,600 F1: Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, which vest in twelve equal monthly installments, beginning on the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, which vest in twelve equal monthly installments, beginning on the date of the grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SCICLONE PHARMACEUTICALS INC
Report date October 13, 2017 · Filed October 16, 2017
Section 16 reporting ended · disclosed 2017-10-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-10-13 transaction · row 1
1 source rowRow 1 · 2017-10-13 · Disposition to issuer · Disposed 135,000 · Balance 0 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2018-06-10 | Direct | 0 |
Reported balance
After 2017-10-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-10-13 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price. F1: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 10, 2008), and became immediately exercisable and vested in full as of June 9, 2009. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.23 · Expires 2019-06-09 | Direct | 0 |
Reported balance
After 2017-10-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-10-13 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price. F3: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 9, 2009), and became immediately exercisable and vested in full as of June 9, 2010. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.01 · Expires 2020-06-10 | Direct | 0 |
Reported balance
After 2017-10-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-10-13 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price. F4: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 10, 2010), and became immediately exercisable and vested in full as of June 10, 2011. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.04 · Expires 2021-06-30 | Direct | 0 |
Reported balance
After 2017-10-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-10-13 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price. F5: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 30, 2011), and became immediately exercisable and vested in full as of June 30, 2012. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.78 · Expires 2022-06-07 | Direct | 0 |
Reported balance
After 2017-10-13 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-10-13 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price. F6: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 7, 2012), and became immediately exercisable and vested in full as of June 7, 2013. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.13 · Expires 2023-06-27 | Direct | 0 |
Reported balance
After 2017-10-13 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2017-10-13 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price. F7: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 27, 2013), and became immediately exercisable and vested in full as of June 27, 2014. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.10 · Expires 2024-06-12 | Direct | 0 |
Reported balance
After 2017-10-13 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2017-10-13 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price. F8: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 12, 2014), and became immediately exercisable and vested in full as of June 12, 2015. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.15 · Expires 2025-06-11 | Direct | 0 |
Reported balance
After 2017-10-13 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2017-10-13 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price. F9: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 11, 2015), and became immediately exercisable and vested in full as of June 11, 2016. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.90 · Expires 2027-06-08 | Direct | 0 |
Reported balance
After 2017-10-13 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2017-10-13 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price. F10: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 11, 2015), and became immediately exercisable and vested in full as of June 11, 2016. Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 8, 2017), and became immediately exercisable and vested in full as of the date ten (10) days prior to the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 10, 2008), and became immediately exercisable and vested in full as of June 9, 2009.
F2: The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price.
F3: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 9, 2009), and became immediately exercisable and vested in full as of June 9, 2010.
F4: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 10, 2010), and became immediately exercisable and vested in full as of June 10, 2011.
F5: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 30, 2011), and became immediately exercisable and vested in full as of June 30, 2012.
F6: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 7, 2012), and became immediately exercisable and vested in full as of June 7, 2013.
F7: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 27, 2013), and became immediately exercisable and vested in full as of June 27, 2014.
F8: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 12, 2014), and became immediately exercisable and vested in full as of June 12, 2015.
F9: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 11, 2015), and became immediately exercisable and vested in full as of June 11, 2016.
F10: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 11, 2015), and became immediately exercisable and vested in full as of June 11, 2016. Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 8, 2017), and became immediately exercisable and vested in full as of the date ten (10) days prior to the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 09, 2025 Filed Sep 11, 2025 18:15 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 17,600 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0001411685-25-000078 · edgardoc.xml · derivative · entry 1 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,600 Underlying: Common Stock · 17,600 shares Expires 2035-09-09 F1 · derivative.exercise_date: Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, which vest in twelve equal monthly installments, beginning on the date of the grant. Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 17:00 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Option (Right to Buy) · Derivative | 14,100 | $0.00 Strike: $3.25 | $0.00 |
DisclosureSEC source: 0001415889-24-023149 · form4-09102024_050911.xml · derivative · entry 1 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,100 Underlying: Common Stock · 14,100 shares Expires 2034-09-06 F1 · derivative.exercise_date: Represents stock options ("Options") granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. Twenty-five percent (25%) of the Options vest on the date of issuance ("Grant Date"), with the remainder vesting in twelve (12) equal monthly installments thereafter, until the Options become fully vested on the one (1) year anniversary of the Grant Date. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 18:00 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $4.85 | $0.00 |
DisclosureSEC source: 0001415889-24-007094 · form4-03062024_060301.xml · derivative · entry 1 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2034-03-04 F1 · derivative.exercise_date: Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, which vest in twelve equal monthly installments, beginning on the date of the grant. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 16:12 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.37 | $0.00 |
DisclosureSEC source: 0001415889-22-002290 · form4-03032022_010344.xml · derivative · entry 1 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-03-01 F1 · derivative.exercise_date: Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, which vest in twelve equal monthly installments, beginning on the date of the grant. Read SEC document |
| March 19, 2021 Filed Mar 22, 2021 19:03 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001415889-21-001607 · form4-03222021_040300.xml · derivative · entry 3 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2021-04-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 19, 2021 Filed Mar 22, 2021 19:03 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | Exercise / conversionCommon Stock | 2,500 | $1.50 | $3,750.00 |
DisclosureSEC source: 0001415889-21-001607 · form4-03222021_040300.xml · nonDerivative · entry 1 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,751 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 16:54 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0001415889-21-000014 · form4-01042021_010129.xml · derivative · entry 1 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2030-12-30 F1 · derivative.exercise_date: Twenty-five percent (25%) of the total number of shares shall be vested immediately on December 31, 2020 (the "Vesting Start Date") and 1/24th of the remaining number of shares shall vest monthly thereafter until all awarded shares are fully vested two (2) years after the Vesting Start Date. Read SEC document |
| August 21, 2020 Filed Aug 24, 2020 16:31 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | PurchaseCommon Stock | 30,000 | $0.69 | $20,700.00 |
DisclosureSEC source: 0001415889-20-002181 · form4-08242020_010800.xml · nonDerivative · entry 1 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Jon S. Saxe and Myrna G. Marshall 1997 Trust Disclosed balance after: 50,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.678 to $0.697, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 21:38 UTC | DURECT CORP DRRX · Entity 75335 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0001082038-20-000009 · edgardoc.xml · derivative · entry 1 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2030-06-17 F1 · derivative.exercise_date: 100% of the total shares of this Grant Dated June 17, 2020 shall vest on the day before the first year anniversary of the Grant Date. Read SEC document |
| April 23, 2020 Filed Apr 27, 2020 17:10 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001415889-20-001060 · form4-04272020_050401.xml · derivative · entry 1 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2030-04-23 F1 · derivative.exercise_date: Twenty-five percent (25%) of the total number of shares shall be vested immediately on April 23, 2020 (the "Vesting Start Date") and 1/24th of the remaining number of shares shall vest monthly thereafter until all awarded shares are fully vested two (2) years after the Vesting Start Date. Read SEC document |
| October 21, 2019 Filed Oct 22, 2019 17:00 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001415889-19-001207 · form4-10222019_051003.xml · derivative · entry 1 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-10-21 F1 · derivative.exercise_date: 25% of the Shares subject to the Option shall vest on date of grant October 21, 2019, and 1/24th of the remaining Shares subject to the Option shall vest on each monthly anniversary of the grant date thereafter. Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 18:12 UTC | DURECT CORP DRRX · Entity 75335 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001082038-19-000020 · edgardoc.xml · derivative · entry 1 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2029-06-19 F1 · derivative.exercise_date: 100% of the total shares of this Grant Dated June 19, 2019 shall vest on the day before the first year anniversary of the Grant Date. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 20:12 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 2,900 | $0.56 | $1,622.84 |
DisclosureSEC source: 0001082038-19-000015 · edgardoc.xml · nonDerivative · entry 20 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 150,000 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 20:12 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 74 | $0.56 | $41.37 |
DisclosureSEC source: 0001082038-19-000015 · edgardoc.xml · nonDerivative · entry 19 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 147,100 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 20:12 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 626 | $0.56 | $349.81 |
DisclosureSEC source: 0001082038-19-000015 · edgardoc.xml · nonDerivative · entry 18 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 147,026 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 20:12 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 3,449 | $0.56 | $1,922.13 |
DisclosureSEC source: 0001082038-19-000015 · edgardoc.xml · nonDerivative · entry 17 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 146,400 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 20:12 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 1,400 | $0.55 | $775.18 |
DisclosureSEC source: 0001082038-19-000015 · edgardoc.xml · nonDerivative · entry 16 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 142,951 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 20:12 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 400 | $0.55 | $221.12 |
DisclosureSEC source: 0001082038-19-000015 · edgardoc.xml · nonDerivative · entry 15 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 141,551 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 20:12 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 1,800 | $0.55 | $993.42 |
DisclosureSEC source: 0001082038-19-000015 · edgardoc.xml · nonDerivative · entry 14 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 141,151 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 20:12 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 300 | $0.55 | $165.00 |
DisclosureSEC source: 0001082038-19-000015 · edgardoc.xml · nonDerivative · entry 13 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 139,351 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 20:12 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 500 | $0.55 | $274.95 |
DisclosureSEC source: 0001082038-19-000015 · edgardoc.xml · nonDerivative · entry 12 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 139,051 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 20:12 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 1,400 | $0.55 | $764.26 |
DisclosureSEC source: 0001082038-19-000015 · edgardoc.xml · nonDerivative · entry 11 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 138,551 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 20:12 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 300 | $0.55 | $163.65 |
DisclosureSEC source: 0001082038-19-000015 · edgardoc.xml · nonDerivative · entry 10 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 137,151 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 20:12 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 1,751 | $0.55 | $955.00 |
DisclosureSEC source: 0001082038-19-000015 · edgardoc.xml · nonDerivative · entry 9 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 136,851 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 20:12 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 100 | $0.55 | $54.51 |
DisclosureSEC source: 0001082038-19-000015 · edgardoc.xml · nonDerivative · entry 8 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 135,100 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 20:12 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 7,898 | $0.54 | $4,303.62 |
DisclosureSEC source: 0001082038-19-000015 · edgardoc.xml · nonDerivative · entry 7 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 135,000 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 20:12 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 100 | $0.54 | $54.44 |
DisclosureSEC source: 0001082038-19-000015 · edgardoc.xml · nonDerivative · entry 6 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 127,102 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 20:12 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 300 | $0.54 | $163.29 |
DisclosureSEC source: 0001082038-19-000015 · edgardoc.xml · nonDerivative · entry 5 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 127,002 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 20:12 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 15 | $0.54 | $8.16 |
DisclosureSEC source: 0001082038-19-000015 · edgardoc.xml · nonDerivative · entry 4 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 126,702 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 20:12 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 200 | $0.54 | $108.78 |
DisclosureSEC source: 0001082038-19-000015 · edgardoc.xml · nonDerivative · entry 3 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 126,687 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 20:12 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 1,200 | $0.54 | $652.56 |
DisclosureSEC source: 0001082038-19-000015 · edgardoc.xml · nonDerivative · entry 2 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 126,487 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 20:12 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 287 | $0.54 | $155.78 |
DisclosureSEC source: 0001082038-19-000015 · edgardoc.xml · nonDerivative · entry 1 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 125,287 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| May 24, 2019 Filed May 28, 2019 19:48 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 4,600 | $0.63 | $2,898.92 |
DisclosureSEC source: 0001082038-19-000014 · edgardoc.xml · nonDerivative · entry 3 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 125,000 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| May 24, 2019 Filed May 28, 2019 19:48 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 21,335 | $0.63 | $13,443.18 |
DisclosureSEC source: 0001082038-19-000014 · edgardoc.xml · nonDerivative · entry 2 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 120,400 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| May 24, 2019 Filed May 28, 2019 19:48 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 4,065 | $0.63 | $2,560.95 |
DisclosureSEC source: 0001082038-19-000014 · edgardoc.xml · nonDerivative · entry 1 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 99,065 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| May 23, 2019 Filed May 28, 2019 16:20 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000597 · form4-05282019_010508.xml · derivative · entry 1 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-05-23 F1 · derivative.exercise_date: 25% of the Shares subject to the Option reported herein shall vest on Vesting Start Date May 23, 2019, and 1/36th of the remaining Shares subject to the Option shall vest on each monthly anniversary of the Vesting Start Date thereafter. Read SEC document |
| May 13, 2019 Filed May 14, 2019 19:01 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 800 | $0.70 | $562.80 |
DisclosureSEC source: 0001082038-19-000011 · edgardoc.xml · nonDerivative · entry 30 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 85,400 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| May 13, 2019 Filed May 14, 2019 19:01 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 2,085 | $0.70 | $1,465.13 |
DisclosureSEC source: 0001082038-19-000011 · edgardoc.xml · nonDerivative · entry 29 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 84,600 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| May 13, 2019 Filed May 14, 2019 19:01 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 37 | $0.70 | $25.97 |
DisclosureSEC source: 0001082038-19-000011 · edgardoc.xml · nonDerivative · entry 28 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 82,515 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| May 13, 2019 Filed May 14, 2019 19:01 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 3,900 | $0.70 | $2,737.41 |
DisclosureSEC source: 0001082038-19-000011 · edgardoc.xml · nonDerivative · entry 27 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 82,478 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| May 13, 2019 Filed May 14, 2019 19:01 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 1,798 | $0.70 | $1,260.40 |
DisclosureSEC source: 0001082038-19-000011 · edgardoc.xml · nonDerivative · entry 26 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 78,578 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| May 13, 2019 Filed May 14, 2019 19:01 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 1,600 | $0.70 | $1,121.44 |
DisclosureSEC source: 0001082038-19-000011 · edgardoc.xml · nonDerivative · entry 25 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 76,780 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| May 13, 2019 Filed May 14, 2019 19:01 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 4,826 | $0.70 | $3,382.06 |
DisclosureSEC source: 0001082038-19-000011 · edgardoc.xml · nonDerivative · entry 24 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 75,180 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| May 13, 2019 Filed May 14, 2019 19:01 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 400 | $0.70 | $280.28 |
DisclosureSEC source: 0001082038-19-000011 · edgardoc.xml · nonDerivative · entry 23 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 70,354 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| May 13, 2019 Filed May 14, 2019 19:01 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 864 | $0.70 | $605.23 |
DisclosureSEC source: 0001082038-19-000011 · edgardoc.xml · nonDerivative · entry 22 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 69,954 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| May 13, 2019 Filed May 14, 2019 19:01 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 1,584 | $0.70 | $1,109.43 |
DisclosureSEC source: 0001082038-19-000011 · edgardoc.xml · nonDerivative · entry 21 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 69,090 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| May 13, 2019 Filed May 14, 2019 19:01 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 1,391 | $0.70 | $974.12 |
DisclosureSEC source: 0001082038-19-000011 · edgardoc.xml · nonDerivative · entry 20 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 67,506 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| May 13, 2019 Filed May 14, 2019 19:01 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 595 | $0.70 | $415.55 |
DisclosureSEC source: 0001082038-19-000011 · edgardoc.xml · nonDerivative · entry 19 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 66,115 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| May 13, 2019 Filed May 14, 2019 19:01 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 300 | $0.70 | $209.16 |
DisclosureSEC source: 0001082038-19-000011 · edgardoc.xml · nonDerivative · entry 18 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 65,520 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
| May 13, 2019 Filed May 14, 2019 19:01 UTC | DURECT CORP DRRX · Entity 75335 | PurchaseCommon Stock | 4,900 | $0.70 | $3,406.97 |
DisclosureSEC source: 0001082038-19-000011 · edgardoc.xml · nonDerivative · entry 17 SAXE JON S · CIK 0001114914 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 65,220 F1 · ownership.nature: Held by the Jon S. Saxe and Myrna G. Marshall 1997 Trust. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.